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Abstract 
Surfactant protein D (SP-D) is a member of the collectin family that plays an 
important role in maintaining pulmonary homeostasis. In this study, we 
demonstrated that SP-D inhibited the proliferation, migration and invasion of A549 
human lung adenocarcinoma cells. We found that SP-D suppressed epidermal 
growth factor (EGF) signaling in A549 cells, H441 human lung adenocarcinoma 
cells and human EGF receptor (EGFR) stable expression CHO-K1 cells. A binding 
study using 125I-EGF demonstrated that SP-D downregulated the binding of EGF to 
EGFR. A ligand blot indicated that SP-D bound to EGFR, and a lectin blot 
suggested that EGFR in A549 cells had both high-mannose type and complex type 
N-glycans. We purified the recombinant extracellular domain of EGFR (soluble 
EGFR = sEGFR), and demonstrated that SP-D directly bound to sEGFR in a Ca2+ 
dependent manner. The binding of SP-D to sEGFR was suppressed by EDTA, 
mannose or N-glycopeptidase F treatment. Mass spectrometric analysis indicated 
that N-glycans in domain III of EGFR were of a high-mannose type. These data 
suggest that SP-D reduces EGF binding to EGFR through the interaction between 
the carbohydrate recognition domain of SP-D and N-glycans of EGFR, and 
downregulates EGF signaling. Our finding suggests the novel type of regulation 
system of EGF signaling involving lectin-to-carbohydrate interaction and 
downregulation of ligand binding. 
 
Keywords: 
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Introduction 
Pulmonary surfactant is a mixture of lipids and proteins that covers alveolar 
surfaces.1, 2 Four specific proteins have been identified designated surfactant 
protein A (SP-A), SP-B, SP-C and SP-D. They are produced by alveolar type II cells 
and Clara cells, which are the major progenitor cells of peripheral airways cells. 
SP-B and SP-C are hydrophobic proteins, which are essential for reducing surface 
tension. SP-A and SP-D are hydrophilic proteins and belong to the collectin 
subgroup of the C-type lectin superfamily. They are mosaic proteins, consisting of 
collagen-like domains and carbohydrate recognition domains (CRD) (lectin domain). 
Each monomeric protein (SP-A, 26-36 kDa; SP-D, 43 kDa) is assembled to form a 
trimeric helix at the collagenous domain, and further multimerized to form an 
octdecamer for SP-A and a dodecamer for SP-D.  
SP-D has been implicated in the regulation of innate immune responses in the 
lung.3, 4 For example, SP-D prevents dissemination of infectious microbes by their 
biological activities including agglutination and growth inhibition.5-7 SP-D also 
promotes clearance of microbes by enhancing phagocytosis in macrophages.8, 9 In 
addition, SP-D interacts with the other pattern-recognition molecules including 
Toll-like receptors (TLRs) and TLR-associated molecules CD14 and MD-2, and 
regulates inflammatory responses.10-12 
It has been suggested that SP-D expression levels are inversely correlated with 
lung cancer progression. The genetic abnormalities in SP-D were associated with 
lung cancer pathogenesis.13, 14 Reduced SP-D expression in bronchoalveolar lavage 
(BAL) fluid was linked to subsequent lung cancer risk.15 Although these studies 
suggested that SP-D suppressed lung cancer progression, the particular 
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mechanisms remain unknown. 
Epidermal growth factor receptor (EGFR) is a member of the ErbB family. By 
binding to epidermal growth factor (EGF), conformational rearrangement occurs, 
which gives rise to an “extended form,” in which the dimerization arm mediates 
homo- and heterodimers, followed by the activation of downstream signaling.16 The 
EGF signaling is involved in a wide variety of cellular events and aberrant 
expression or dysregulation of EGFR has been implicated in cell transformation and 
cancer.17 EGFR tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib show 
anti-tumor activity in patients with advanced non-small cell lung cancer, however, 
there are clinical problems in that EGFR-TKIs have a limited degree of benefit to 
patients with a non mutant EGFR and patients with a mutant EGFR develop 
disease progression by acquiring resistance.18, 19 
In the present study, we found that SP-D downregulated EGF signaling and 
suppressed the progression of lung cancer cells. We demonstrated that SP-D bound 
to EGFR via lectin activity and reduced EGF binding. We also determined the 
structure of the relevant N-glycans. The results indicated that SP-D exerts tumor 
suppressive effects by interfering with the binding of EGF to EGFR. 
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Results 
SP-D suppresses the proliferation, migration and invasion of A549 cells 
First, we examined the effects of SP-D on the proliferation of lung cancer cells. A549 
human lung adenocarcinoma cells were incubated with 1 or 10 µg/ml of SP-D and 
the cell proliferation was assayed after 24, 48 and 72 h. As shown in Fig. 1A, left 
panel, SP-D suppressed the proliferation of A549 cells. Dose dependency was also 
confirmed (Fig. 1A, right panel).  
We evaluated the effects of SP-D on the migration and invasion of A549 cells. 
When SP-D was added, the number of EGF-induced migration and invasion cells 
was significantly decreased (Fig. 1B and 1C). It was revealed that SP-D suppressed 
the invasive ability of A549 cells more effectively than it did the migration ability. 
 
SP-D suppresses EGF signaling in A549 cells, H441 cells and human EGFR stable 
expression CHOK1 cells 
Next, we assessed the effects of SP-D on EGF signaling in A549 cells. As shown in 
Fig. 1D, SP-D suppressed the phosphorylation of EGFR, Erk and Akt in a dose 
dependent manner. The same results were obtained with H441 cells (data not 
shown) and human EGFR stable expression CHO-K1 cells (Fig 1E).  
 
SP-D reduces the binding of EGF to EGFR in A549 cells 
To determine the mechanisms by which SP-D suppressed EGF signaling in A549 
cells, a binding analysis of 125I-EGF to EGFR in the presence and absence of SP-D 
was performed. SP-D significantly reduced the saturation level of bound EGF in 
A549 cells (Fig. 2A). When suppression patterns were examined, SP-D suppressed 
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EGF binding in a dose dependent manner up to 75 g/ml (Fig. 2B). These data 
suggested that SP-D blocked the binding of EGF and, consequently, suppressed 
EGF signaling. 
 
SP-D binds to EGFR in A549 cells 
Next, we examined whether SP-D bound to EGFR in A549 cells by using a ligand 
blot. The whole cell lysate of A549 cells was immunoprecipitated with anti-EGFR 
monoclonal antibody Ab-11, subjected to SDS-PAGE and finally a ligand blot 
analysis was performed. As shown in Fig. 3A, SP-D bound to EGFR of A549 cells on 
the PVDF membrane. To examine which type of N-glycans existed in EGFR of A549 
cells, lectin blot analysis using concanavalin A and DSA was performed. Both 
concanavalin A and DSA reacted with EGFR (Fig. 3B), suggesting that EGFR of 
A549 cells had both high-mannose type and complex type of N-glycans.  
 
SP-D binds to N-glycans of EGFR in a Ca2+ dependent manner 
To examine the particular mechanisms by which SP-D directly interacts with EGFR, 
we prepared recombinant sEGFR. Recombinant sEGFR with or without 
N-glycopeptidase F treatment was subjected to SDS-PAGE and lectin blot analysis 
was performed. It was found that the molecular mass was decreased (Fig. 4A) and 
the reactivity against concanavalin A and DSA was diminished (Fig. 4B) by 
N-glycopeptidase F treatment, suggesting that both a high-mannose type and a 
complex type of N-glycans were successfully removed from sEGFR. 
We next examined whether SP-D bound to sEGFR with or without 
N-glycopeptidase F treatment by using ligand blotting. As shown in Fig. 4C, the 
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binding of SP-D to sEGFR was inhibited by N-glycopeptidase F treatment. 
We further examined whether SP-D bound to sEGFR coated onto microtiter wells 
and conversely whether sEGFR bound to coated SP-D. SP-D exhibited a 
concentration-dependent binding to coated sEGFR in the presence of Ca2+ (Fig. 4D, 
left panel). The binding of sEGFR to coated SP-D indicated the same result (Fig. 4D, 
right panel). Inclusion of 5 mM EDTA instead of Ca2+ inhibited the binding, 
indicating that the binding of SP-D to sEGFR was Ca2+ dependent (Fig. 4E). It was 
also observed that excess mannose blocked the binding of SP-D to sEGFR (Fig. 4F). 
When N-glycans of sEGFR were cleaved by N-glycopeptidase F, the binding of SP-D 
to sEGFR was suppressed, indicating that SP-D binds to sEGFR via its N-glycans 
(Fig. 4G). 
We further determined the binding parameters of SP-D with sEGFR using 
surface plasmon resonance analysis. The passage of SP-D at various concentrations 
over immobilized sEGFR on a sensor chip yielded an association rate constant of ka 
= 4.8 ×104 M-1 S-1 and dissociation rate constant of kd = 1.7 ×10-3 S-1, for a consequent 
dissociation constant of KD (kd/ka) = 3.2 ×10-8 M. The injection of 10 mM EDTA 
resulted in the complete dissociation of SP-D (Fig. 4H). When an excess-mannose 
containing running buffer was used, there was no detectable interaction of SP-D 
and sEGFR (Fig. 4I). When sEGFR treated with N-glycopeptidase F was used, the 
interaction was also completely suppressed (Fig. 4J). These results suggested that 
the CRD of SP-D is involved in the interaction with N-glycans of sEGFR.  
 
Structures of N-glycans of sEGFR 
Since SP-D is known to preferentially bind to mannose,3 we assumed that a 
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high-mannose type of N-glycans of EGFR was involved in the interaction of SP-D 
and EGFR. We examined the structures of N-glycans of EGFR by MS analysis. 
Purified sEGFR was subjected to enzymatic proteolysis, and the glycosylated 
peptides were isolated by reversed phase chromatography. Amino acid sequencing of 
the peptide backbone and the site of glycosylation were determined by CID 
multi-stage tandem MS. We found that Asn328 and Asn337 had high-mannose type 
N-glycans but all other Asn in N-X-T/S N-glycosylation consensus sequences and 
Asn32 in N-X-C atypical N-glycosylation motif had complex type N-glycans. The 
structural analysis indicated that the dominant population of N-glycans on Asn328 
of EGFR were high-mannose types composed of 5 mannose (so called Man5) or 
Man6, whereas those on Asn 337 were Man5, Man6, Man7 or Man8 (Fig. 5A and 
supplementary Fig. 1A and 1B). Furthermore, any unglycosylated peptides 
containing Asn328 (m/z 1175.6 for monoisotopic mass) or Asn337 (m/z 1900.0) were 
not found in a peptide mixture, indicating that both Asn328 and Asn 337 are nearly 
100% glycosylated. These results are summarized in Fig. 5B. 
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Discussion 
In this study, we examined the mechanisms by which SP-D suppresses lung cancer 
progression. SP-D inhibited the proliferation, migration and invasion of A549 lung 
human adenocarcinoma cells. We found that SP-D suppressed EGF signaling in 
A549 cells, H441 cells, and human EGFR stable expression CHO-K1 cells. A binding 
study using 125I-EGF suggested that SP-D blocked the binding of EGF to EGFR. 
Ligand and lectin blots suggested that SP-D bound to EGFR of A549 cells, and 
N-glycans of EGFR in A549 cells were both high-mannose and complex types. We 
purified recombinant sEGFR, and proved that SP-D directly bound to sEGFR in a 
Ca2+ dependent manner. Surface plasmon resonance analysis revealed that the 
dissociation constant of SP-D and sEGFR was KD = 3.2 ×10-8 M. In the presence of 
EDTA or mannose, the binding of SP-D to sEGFR was completely suppressed and 
N-glycopeptidase F treatment of sEGFR also inhibited the binding of SP-D to 
sEGFR. These data suggested that the CRD of SP-D and N-glycans of EGFR were 
involved in the interaction between SP-D and EGFR. 
We demonstrated that SP-D treatment significantly decreased the saturation 
level of EGF binding (Fig. 2). These results are consistent with the data indicating 
that SP-D treatment downregulated EGF signaling in A549 cells (Fig. 1). Together 
with the fact that SP-D directly binds to the extracellular domain of EGFR (Fig. 4), 
probably via N-glycans in domain III of EGFR (Fig. 4-5), it is possible that SP-D 
binding to EGFR affects conformational changes in EGFR or EGFR dimerization, 
and subsequently alters the binding characteristics of EGF to EGFR.  
Recent studies have revealed that binding of EGF to EGFR shows negative 
cooperativity;20, 21 EGF binds with high affinity to the first site on the dimer, induces 
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formation of an asymmetric dimer and binds with substantially lower affinity to the 
second site on the dimer. Structural analysis of SP-D and the EGFR heterodimer 
would be of help toward further understanding of the mechanisms of interaction of 
SP-D and EGFR. 
The functional regulation of EGFR by N-glycans has been investigated.22-29 Some 
of the regulation mechanisms include the interaction of extracellular molecules and 
N-glycans of EGFR. It has been reported that galectin-3, which is secreted to the 
cell surface, interacts with poly-N-acetyl lactosamine in the N-glycans of EGFR, and 
delays the endocytosis of EGFR.27 It was also demonstrated that the binding of 
ganglioside GM3 to GlcNAc termini of N-glycans of EGFR by 
carbohydrate-to-carbohydrate interaction results in the inhibition of EGF signaling 
without affecting EGF binding to EGFR.28, 29 In the present study, we have 
demonstrated that SP-D directly binds to EGFR via its N-glycans. SP-D binding 
decreases the EGF binding to EGFR and subsequently downregulates EGF 
signaling, suggesting the novel type of EGFR regulation involving 
lectin-to-carbohydrate interaction and downregulation of ligand binding. 
In this study, the assignment of the structures of N-glycans of EGFR was 
conducted by MS (Fig. 5). Although there are many differences with the data 
previously reported,30 which were based on susceptibility to N-glycopeptidase F and 
Endo H digestion, we believe that the accuracy has been improved. 
At present, SP-D is often implicated in lung cancer progression. The genetic 
abnormalities in SP-D are associated with lung cancer pathogenesis.13, 14 Reduced 
SP-D expression in BAL fluid has relevance to subsequent lung cancer risk.15 The 
level of SP-D in BAL fluid of patients with idiopathic pulmonary fibrosis (IPF) is 
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decreased31 and the incidence of lung cancer is increased in patients with IPF.32-34 
As we have suggested, SP-D potentially interacts with EGFR or other receptors 
with N-glycan(s), and modulates those functions. The similar mechanisms might be 
involved in the antitumor effects of SP-D observed in the previous studies. 
It has been reported that some primary lung cancers expressed SP-D.35 The levels 
of SP-D are increased in the pleural effusion and serum from some patients with 
lung cancer.36, 37 Murine lung tumors express SP-D38 and serum levels of SP-D are 
increased in mice with lung tumors.39 Primary lung adenocarcinoma originates from 
the progenitor cells of peripheral airways cells that have potential to produce SP-D. 
It is possible that these lung cancers are regulated by SP-D by autocrine 
mechanisms.    
Since SP-D is a constituent of a pulmonary surfactant that exists in the epithelial 
lining fluid of the alveolus, it is difficult to determine its exact concentration in vivo. 
Nonetheless, its concentration can be estimated based on the recovery of the 
proteins in bronchoalveolar lavage fluids and the extrapolated hypophase volume, 
and the concentration of SP-D was calculated as ~60 g/ml in healthy volunteers.31, 
40-43 Although its concentration appears to vary in a disease state, the SP-D 
concentrations used in this study are within the best estimates of the physiological 
ranges.  
EGFR is one of the most important therapeutic targets in cancer. SP-D plays a 
role in suppressing lung cancer progression by direct binding to an extracellular 
domain of EGFR; therefore, it is possible that they are effective for patients without 
EGFR gene mutation and resistant to EGFR-TKI treatment. Elucidating the 
antitumor effects of SP-D may provide important clues for establishing new 
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therapeutic strategies for lung cancers, especially those resistant to existing 
therapies. 
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Materials and methods 
Reagents and antibodies 
Human recombinant EGF was purchased from Sigma Aldrich (St. Louis, MO) and 
125I-EGF was purchased from PerkinElmer (Waltham, MA). The polyclonal 
antibodies to Akt and Erk and phospho-specific polyclonal antibodies to EGFR (Tyr 
1068), Akt and Erk were purchased from Cell Signaling Technology (Danvers, MA). 
The polyclonal antibody to EGFR was from Millipore (Billerica, MA). The 
monoclonal antibody to EGFR Ab-11 was from NeoMarkers (Fremont, CA). The 
polyclonal antibody to His-tag was from MBL (Nagoya, Japan). HRP (horseradish 
peroxidase) conjugated anti-rabbit and anti-mouse IgG were from Promega 
(Madison, WI). To produce the polyclonal antibody against human SP-D, purified 
recombinant human SP-D was injected into New Zealand White rabbits 
intramuscularly and the antiserum was purified.10, 12 Hybridomas producing 
anti-SP-D monoclonal antibody 7C6 were established and 7C6 was prepared as 
described previously.44 The anti-SP-D polyclonal and monoclonal antibodies reacted 
with SP-D purified from human alveolar lavage fluids or recombinant human SP-D 
but not with SP-A.12 All other chemicals and reagents were purchased from Wako 
Pure Chemicals (Osaka, Japan) unless otherwise noted. 
  
Cell culture 
The A549 human lung adenocarcinoma cell line was obtained from ATCC 
(Manassas, VA) and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Sigma Aldrich) with 10% (v/v) fetal calf serum (FCS). The H441 human lung 
adenocarcinoma cell line was obtained from ATCC and maintained in RPMI 1640 
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(Sigma Aldrich) with 10% (v/v) FCS. The Flp-In CHO cell line was obtained from 
Invitrogen (Carlsbad, CA), and maintained in Ham’s F12 medium (Sigma Aldrich) 
with 10% (v/v) FCS. CHO-K1 cells expressing SP-D were grown in glutamate-free 
Glasgow minimum essential medium (Sigma Aldrich) containing 10% (v/v) dialyzed 
FCS.10, 45 
 
Purification of recombinant human SP-D 
Recombinant human SP-D was purified as described previously.10, 45 The physical 
forms of the recombinant collectins used in this study were confirmed by rotary 
shadow electron microscopy.12 
 
Cell proliferation assay 
A549 cells were plated in a 96-well plate and incubated with indicated 
concentration of SP-D. Cell proliferation was assayed using a WST-1 reagent 
(Takara, Japan).  
 
Cell migration and invasion assays 
Cell migration and invasion assays were conducted using the Transwell double 
chamber (BD BioCoat Matrigel Invasion Chamber. BD Bioscience, Bedford, MA). 
A549 cells were seeded into the upper insert in Dulbecco’s Modified Eagle’s Medium 
(DMEM) with 0.1% (v/v) FCS, and DMEM with 10% (v/v) FCS as a chemoattractant 
was added to the bottom wells. After fixation with 4% paraformaldehyde/phosphate 
buffered saline (PBS) (-), the cells were permeabilized and stained with DAPI (200 
ng/ml) in PBS (-). The cells were counted under a fluorescence microscope 
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(KEYENCE, Osaka). 
 
Establishment of human EGFR and the extracellular domain of EGFR (sEGFR) 
stable expression cells 
To establish human EGFR and sEGFR stable expression cells, the Flp-In system 
(Invitrogen) was used. cDNA for human EGFR and the myc-His tagged sEGFR 
(residues 1-618 of the mature protein) were subcloned into a pcDNA5/FRT 
expression vector, and transfected into Flp-In CHO-K1 cells with pOG44 plasmids. 
 
Protein sample preparation and Western blotting 
Cells were harvested in a lysis buffer (20 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 5 mM 
ethylenediaminetetraacetic acid, 1% (w/v) Nonidet P-40, 10% (w/v) glycerol, 5 mM 
sodium pyrophosphate, 10 mM NaF, 1 mM sodium orthovanadate, 10 mM 
β-glycerophosphate, 1 mM PMSF, 2 mg/ml aprotinin, 5 mg/ml leupeptin and 1 mM 
dithiothreitol) and centrifuged at 15,000 X g for 10 min at 4°C, and the resultant 
supernatant was used as a protein sample. The samples were separated by 
SDS-PAGE and transferred to PVDF membranes (Millipore). After blocking, the 
blots were probed with an indicated antibody and immunoreactive bands were 
visualized using a chemiluminescence reagent (SuperSignal West Pico, Pierce, 
Rockford, IL). Densitometric analysis was performed by using a Luminous analyzer. 
 
Binding analysis of 125I-EGF to EGFR 
A549 cells were seeded at a density of 7 × 104 cells/well in 24-well plate and allowed 
to adhere overnight. The cells were washed with DMEM containing 0.1% (w/v) 
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bovine serum albumin (BSA), and incubated with the indicated concentration of 
SP-D for 2 h at 37°C in the same medium. The medium was removed, the cells were 
washed with the same medium and 125I-EGF was added in the presence of unlabeled 
EGF in order to reach the indicated concentration. Nonspecific binding was 
determined by adding 1,000 nM cold EGF. After incubation for 2 h at 4°C, the cells 
were washed three times with ice-cold PBS (-) containing 0.1% (w/v) BSA and 
hydrolyzed in 0.5 ml of 1 N NaOH for 30 min at room temperature. The 
radioactivity of the cell lysate was quantified using a -counter.  
 
Immunoprecipitation 
The whole cell lysate of A549 cells was precipitated with anti-EGFR monoclonal 
antibody Ab-11 (0.8 µg) and Protein A-Sepharose (15 µl) by gentle shaking at 4°C for 
16 h. The beads were washed four times with a lysis buffer and resuspended in the 
SDS sample buffer. The samples were subjected to SDS-PAGE after boiling for 5 
min under reducing conditions and transferred onto PVDF membranes. The 
membranes were used for Western blot, lectin blot and ligand blot. 
 
Ligand blot 
EGFR in A549 cells were immunoprecipitated with anti-EGFR monoclonal antibody 
Ab-11, electrophoresed and transferred onto PVDF membranes. sEGFR treated 
with or without N-glycopeptidase F was also electrophoresed and transferred onto 
PVDF membranes. After nonspecific binding was blocked with 10 mM HEPES (PH 
7.4) containing 0.15 M NaCl, 5 mM CaCl2 and 5% (w/v) BSA, these membranes were 
incubated with SP-D (1 µg/ml) for 16 h. After washing with 20 mM Tris-HCl (PH 
17 
 
7.4) containing 0.15 M NaCl, 0.05% (v/v) Tween-20, bound SP-D was detected by an 
anti-human SP-D polyclonal antibody or monoclonal antibody 7C6.  
 
Lectin blot 
EGFR in A549 cells were immunoprecipitated, electrophoresed and transferred onto 
PVDF membranes. sEGFR treated with or without N-glycopeptidase F was also 
electrophoresed and transferred onto PVDF membrane. These membranes were 
blocked with 3% (w/v) BSA in Tris-buffered saline containing 0.1% (v/v) Tween 20. 
The membranes were then incubated with biotinylated concanavalin A or 
biotinylated DSA (J-Oil Mills, Tokyo, Japan) (4 µg/ml) at room temperature for 1 h 
followed by incubation with HRP-labeled streptavidin.  
 
Purification of recombinant sEGFR 
sEGFR stable expression cells were cultured and the medium was collected. The 
expressed myc-His tagged sEGFR was purified by a series of column 
chromatographies on HisTrap HP5 (GE Healthcare), Mono Q (GE Healthcare) and 
HiLoad Superdex 200 pg (GE Healthcare) using the AKTA purifier system (GE 
Healthcare).46 Purity of sEGFR was confirmed by SDS-PAGE. 
 
Treatment of sEGFR with N-glycopeptidase F 
sEGFR was treated with N-glycopeptidase F (Takara, Japan) (10 milliunit/25 µg of 
protein) for 24 h at 37°C under non-reducing conditions. After incubation, the state 
of cleavage was confirmed by SDS-PAGE and a lectin blot. The cleavage was 
dialyzed against PBS (-) before being used for ligand blotting, ELISA and surface 
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plasmon resonance analysis. 
 
Binding assay of SP-D to sEGFR with ELISA 
sEGFR (100 ng/well) was coated onto microtiter wells, and nonspecific binding was 
blocked with 10 mM HEPES buffer (PH 7.4) containing 0.15 M NaCl, 5 mM CaCl2 
and 5% (w/v) BSA (buffer A). The indicated concentrations of SP-D in buffer A were 
added and incubated for 2 h. After incubation, the wells were washed with PBS (-) 
containing 0.05% (v/v) Tween-20 (PBST) and further incubated with an anti-SP-D 
polyclonal antibody (1 µg/ml) for 2 h. After washing with PBST, HRP-conjugated 
goat anti-rabbit IgG was added and further incubated for 1 h. Finally, a peroxidase 
reaction was performed by using o-phenylenediamine as a substrate. The 
interaction of SP-D with sEGFR was also analyzed with coated SP-D (500 ng/well). 
The binding of sEGFR to SP-D was detected by an anti-His-tag polyclonal antibody 
(1 µg/ml). To eliminate the effect of Ca2+ on the binding, in some experiments we 
included 5 mM EDTA instead of CaCl2 in buffer A. To examine the effect of mannose, 
we included 200 mM mannose in buffer A. 
 
Binding assay of SP-D to sEGFR with surface plasmon resonance analysis  
sEGFR (20 µg/ml) in 10 mM sodium acetate (pH 5.0) was immobilized on a sensor 
chip C1 of the Biacore 3000 system (Biacore, Uppsala, Sweden), according to the 
manufacturer’s specifications. For the running buffer, 25 mM HEPES, pH 7.4, 
containing 0.15 M NaCl and 5 mM CaCl2 and 0.005% surfactant P-20 were used. 
The association rate constant (ka) and the dissociation rate constant (kd) were 
calculated according to the BIAevaluation software (Version 3.1, Biacore AB).  
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Isolation of glycosylated peptides 
The purified sEGFR was S-carbamidomethylated and digested with 1% (w/w) each 
of lysyl endopeptidase (Wako Pure Chemicals, Japan) and trypsin (Promega) at 
37°C for 16 h. The glycosylated peptides in the digest were enriched by the 
hydrophilic affinity method as described previously.47 Reversed phase 
chromatography was carried out on an Inertsil WP300 C8 column (1.0 X 150 mm, 
300 Å, GL Sciences, Tokyo).  
 
Mass spectrometry 
The glycan profile and amino acid sequence of glycosylated peptides were obtained 
by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) 
using a pulsed nitrogen laser (337 nm) and nanoelectrospray ionization MS. For 
glycan profiling, MALDI time-of-flight (TOF) measurements were performed using 
a Voyager DE Pro mass spectrometer (AB Sciex, Framingham, MA) in linear 
mode.48 Amino acid sequencing was carried out by collision-induced dissociation 
(CID) and multiple-stage tandem MS using an LTQ-XL mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA).49 The glycosylated peptide samples were dissolved 
in a 0.1% formic acid and 20% (v/v) methanol solution and directly infused by using 
a spray tip (New Objective, Woburn MA) for infusion mode nanoelectrospray 
ionization MS. The collision gas was helium. 
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Figure Legends 
 
Fig. 1. SP-D suppresses the cell proliferation, migration and invasion by 
suppressing EGF signaling 
(A, left panel) A549 cells were plated in a 96-well plate (1 × 103 cells/well), 
maintained in DMEM with 10% (v/v) FCS, and incubated with 10 µg/ml of SP-D at 
37°C. The cell proliferation was assayed after 24, 48 and 72 h using WST-1 reagent.  
(A, right panel) A549 cells were incubated with 1 or 10 µg/ml of SP-D, and the cell 
proliferation was assayed after 48 h. The data shown are the means ± S.D. (error 
bars) from three independent experiments. **p < 0.01 (compared with the control). 
(B) (C) A549 cells were seeded into the upper insert of a transwell double chamber 
in DMEM with 0.1% (v/v) FCS and EGF (10 ng/ml) with or without SP-D (10 µg/ml) 
and DMEM with 10% (v/v) FCS was added to the bottom wells as a chemoattractant. 
A control insert was used for migration assay (B) and a matrigel insert was used for 
invasion assay (C). After 22 h, cells migrating or invasive cells were fixed, stained 
with DAPI and counted under a microscope. The data shown are the means ± S.D. 
(error bars) from three independent experiments. **p < 0.01 (compared with the 
control). 
(D) A549 cells were serum starved overnight and incubated with various 
concentrations of SP-D for 2 h at 37°C. After incubation, the cells were washed in a 
medium without serum and stimulated with 10 ng/ml of EGF for 10 min at 37°C. 
The cell lysate was prepared and 15 µg protein/lane were subjected to Western 
blotting using indicated antibodies. The data are representative of three 
independent experiments. The right panel displays the densitometric evaluation 
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and the data shown are the means ± S.D. (error bars) from three independent 
experiments.  
(E) The same experiment as panel (D) was performed using human EGFR stable 
expression CHO-K1 cells. The data are representative of three independent 
experiments. The right panel displays the densitometric evaluation and the data 
shown are the means ± S.D. (error bars) from three independent experiments. 
 
Fig. 2. SP-D reduced the binding of EGF to EGFR in A549 cells 
(A) 125I-EGF binding to A549 cells in the presence and absence of SP-D. Binding of 
EGF to the cells was evaluated using a -counter as described in “Materials and 
Methods.” 
(B) Dose dependent suppression of EGF binding by SP-D. Binding of EGF to the 
cells was evaluated using a -counter as described in “Materials and Methods.” The 
data are expressed as relative values with the binding in the absence of SP-D being 
100%. 
 
Fig. 3. SP-D binds to EGFR in A549 cells 
(A) Whole cell lysate of A549 cells was immunoprecipitated with anti-EGFR 
monoclonal antibody Ab-11 (0.8 µg) at 4°C for 16 h. The samples and BSA (200 
ng/lane) were subjected to SDS-PAGE and transferred onto PVDF membranes. The 
membranes were incubated with SP-D (1 µg/ml) for 16 h. The membranes were then 
incubated with an anti-human SP-D polyclonal antibody and monoclonal antibody 
7C6 followed by HRP-labeled anti-rabbit IgG and anti-mouse IgG. 
(B) The membranes were prepared similarly to panel (A) and subjected to lectin 
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blotting using biotinylated concanavalin A and DSA. 
 
Fig. 4. Binding assay of SP-D to sEGFR  
(A) sEGFR was produced in Flp-In CHO-K1 cells and purified as described in 
“Materials and Methods.” 0.5 µg of proteins with or without N-glycopeptidase F 
treatment were subjected to SDS-PAGE, followed by Coomassie Brilliant Blue 
R-250 staining. 
(B) sEGFR with or without N-glycopeptidase F treatment was electrophoresed 
under reducing conditions and transferred onto PVDF membranes. The membranes 
were subjected to lectin blotting using biotinylated concanavalin A and DSA. 
(C) sEGFR with or without N-glycopeptidase F treatment and BSA was 
electrophoresed under reducing conditions and transferred onto the PVDF 
membrane. The membrane was incubated with SP-D (1 µg/ml) for 16 h. The 
membrane was then incubated with anti-human SP-D monoclonal antibody 7C6 
followed by HRP-labeled anti-mouse IgG. 
(D, left panel) The indicated concentrations of SP-D were incubated with sEGFR 
(100 ng/well) or BSA (100 ng/well) coated onto microtiter wells at room temperature 
for 2 h in the presence of 5 mM CaCl2. ELISA was performed as described under 
“Materials and Methods.” The data shown are the means ± S.D. (error bars) from 
three independent experiments. *p < 0.05, **p < 0.01 (compared with the control). 
(D, right panel) The indicated concentrations of sEGFR were incubated with SP-D 
(500 ng/well) or BSA (500 ng/well) coated onto microtiter wells at room temperature 
for 2 h in the presence of 5 mM CaCl2.  
(E) The same experiment as panel (D) was performed in the presence of 5 mM EDTA 
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instead of CaCl2.  
(F) The same experiment as panel (D) was performed in the presence of 5 mM CaCl2 
with 0.2 M mannose.  
(G) The same experiment as panel (D) was performed with sEGFR with or without 
N-glycopeptidase F treatment.  
(H) The parameters of bindings of sEGFR to SP-D were determined by surface 
plasmon resonance analysis as described under “Materials and Methods.” 
Sensorgrams for the bindings of various concentrations of SP-D to sEGFR 
immobilized on a sensor chip are shown. After the dissociation time, 10 mM EDTA 
were injected for 1 min.  
(I) The same experiment as panel (H) was performed with 0.2 M mannose at SP-D 
injection.  
(J) The same experiment as panel (H) was performed with sEGFR with 
N-glycopeptidase F treatment. RU, response units. 
 
Fig. 5. Structures of N-glycans of sEGFR produced in CHOK1 cells 
(A) MALDI linear TOF mass spectrum of the glycosylated peptides including 
Asn328 (upper panel) and Asn337 (lower panel) of sEGFR produced in CHO-K1 
cells. The intensity of the signals allows a rough estimation of the relative 
abundances of the molecules.  
(B) The summary of N-glycans of EGFR produced in CHO-K1 cells. The illustration 
indicates the structure of N-glycans of sEGFR. Blue square, N-acetylglucosamine; 
green circle, mannose; yellow circle, galactose; purple diamond, sialic acid; red 
triangle, fucose. 
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